Apimeds Pharmaceuticals US, Inc.
APUS
$1.75
-$0.06-3.32%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -48.05% | 179.85% | 7,822.22% | 4,584.48% | 12,839.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.71% | 187.91% | 1,438.85% | 381.74% | 744.56% |
| Operating Income | 50.71% | -187.91% | -1,438.85% | -381.74% | -744.56% |
| Income Before Tax | 45.04% | -202.27% | -1,144.88% | -358.98% | -660.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.04% | -202.27% | -1,144.88% | -358.98% | -660.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.04% | -202.27% | -1,144.88% | -358.98% | -660.05% |
| EBIT | 50.71% | -187.91% | -1,438.85% | -381.74% | -744.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 55.73% | -65.75% | -505.32% | -123.21% | -358.76% |
| Normalized Basic EPS | 55.76% | -65.41% | -501.69% | -122.86% | -359.50% |
| EPS Diluted | 55.73% | -65.75% | -505.32% | -123.21% | -358.76% |
| Normalized Diluted EPS | 55.76% | -65.41% | -501.69% | -122.86% | -359.50% |
| Average Basic Shares Outstanding | 24.11% | 82.44% | 105.50% | 105.50% | 65.58% |
| Average Diluted Shares Outstanding | 24.11% | 82.44% | 105.50% | 105.50% | 65.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |